Medically reviewed by Gagandeep Brar, MDMedically reviewed by Gagandeep Brar, MD The Janus kinase 2 (JAK2) gene directs cells to make the JAK2 protein, which stimulates cell growth and division.

A 45-year-old woman was evaluated in the rheumatology clinic because of possible IgG4-related disease. She had polyclonal ...

Shares of Incyte INCY have risen 12.7% in the past six months against the industry’s decline of 0.5%. The stock has also ...

AVITA's large addressable market, high gross margins, and low valuation suggest the potential for 154% stock upside. Find out ...

Although Jakafi has been approved for patients with higher-risk myelofibrosis, those with lower-risk disease may also benefit ...

An expert explained the importance of education and involvement in care for patients with myeloproliferative neoplasms.

Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the EADV 2024 Congress ...

GlobalData’s report assesses the drugs in the Leptin Receptor pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.

China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on September 24, 2024, the New Drug Application (NDA) for ...

Researchers presented the case of a patient with MF treated with ruxolitinib who had cavitary lung lesions caused by P jirovecii infection.

Opzelura, a novel cream formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration for the topical treatment of nonsegmental vitiligo in ...